Therapeutic combinations and methods including irm compounds

Abstract

The present invention provides therapeutic combinations that include an immune response modifier (IRM) component and an anti-inflammatory component. The inventions further provide methods of treating a condition by administering to one having the condition a therapeutic combination that includes an IRM component and an anti-inflammatory component.

What is claimed is: 
     
         1 . A therapeutic combination comprising:
 a) an IRM compound agonist of at least one of TLR7 or TLR8 in an amount effective to treat the neoplastic tumors, where the IRM compound comprises an imidazoquinoline amine; and   (b) an anti-inflammatory comprising a glucocorticoid, a non-steroidal anti-inflammatory drug, an immunosuppressant, an immunotherapeutic, or combinations thereof.   
     
     
         2 . The therapeutic combination of  claim 1 , wherein the anti-inflammatory compound comprises a glucocorticoid selected from the group consisting of alclometasone, amcidonide, beclomethasone, betamethasone, budesonide, ciclesonide, clobetasol, clobetasone, corticosterone, cortisone, deflazacort, desonide, desoximetasone, dexamethasone, diflucotolone, diflorasone, flumethasone, flunisolide, fluocinolone, fluocinonide, fluocortolone, fluorometholone, flurandrenolone, flurandrenolide, fluticasone, halcinonide, halobetasol, hydrocortisone, methylprednisolone, mometasone, paramethasone, prednisolone, and triamcinolone. 
     
     
         3 . The therapeutic combination of  claim 1 , wherein the anti-inflammatory compound comprises a non-steroidal anti-inflammatory drug selected from the group consisting of aceclofenac, acemetacin, aminopyrine, azapropazone, benzydamine, bromfenac, bufexamac, carprofen, cinnoxicam, dexketoprofen, diclofenac, diflunisal, dipyrone, etodolac, felbinac, fenbufen, fenoprofen, fentiazac, flufenamic acid, flurbiprofen, ibuprofen, indobufen, indomethacin, indoprofen, ketoprofen, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, niflumic acid, nimesulide, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, a salicylate, sulindac, suprofen, tenoxicam, tiaprofenic acid, tolfenamic acid, and tolmetin. 
     
     
         4 . The therapeutic combination of  claim 1 , wherein the anti-inflammatory compound comprises an immunosuppressant selected from the group consisting of acetretin, alefacept, anakinra, an analgesic, auranofin, azathioprine, cyclophosphamide, cyclosporin, etanercept, isotretinoin, leflunomide, methotrexate, minocycline, montelukast, mycophenalate, penicillamine, pimecrolimus, rosiglitazone, sirolimus, sulfasalazine, tacrolimus, tazarotene, verteporfin, zafirlukast, and zileuton. 
     
     
         5 . The therapeutic combination of  claim 1 , wherein the anti-inflammatory compound comprises an immunotherapeutic selected from the group consisting of an antibody directed against a proinflammatory molecule, adalimumab, efalizumab, infliximab, omalizumab, and mepolizumab. 
     
     
         6 . The therapeutic combination of  claim 1 , wherein the imidazoquinoline amine is a amide substituted imidazoquinoline amine, sulfonamide substituted imidazoquinoline amine, or a urea substituted imidazoquinoline amine. 
     
     
         7 . The therapeutic combination of  claim 1 , wherein the IRM compound is N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide. 
     
     
         8 . The therapeutic combination of  claim 1 , wherein the IRM is N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide and the anti-inflammatory component is prednisone. 
     
     
         9 . The therapeutic combination of  claim 1 , wherein the IRM compound is other than 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine. 
     
     
         10 . A method of treating neoplastic tumors, comprising administering to a subject having the neoplastic tumors a therapeutic combination that comprises
 (a) an IRM compound agonist of at least one of TLR7 or TLR8 in an amount effective to treat the neoplastic tumors, where the IRM compound comprises an imidazoquinoline amine; and   (b) an anti-inflammatory compound in an amount effective to limit a side effect of administering the IRM compound;   wherein the anti-inflammatory compound comprises a glucocorticoid, a non-steroidal anti-inflammatory drug, an immunosuppressant, an immunotherapeutic, or combinations thereof   
     
     
         11 . The method of  claim 10 , wherein the anti-inflammatory compound comprises a glucocorticoid selected from the group consisting of alclometasone, amcidonide, beclomethasone, betamethasone, budesonide, ciclesonide, clobetasol, clobetasone, corticosterone, cortisone, deflazacort, desonide, desoximetasone, dexamethasone, diflucotolone, diflorasone, flumethasone, flunisolide, fluocinolone, fluocinonide, fluocortolone, fluorometholone, flurandrenolone, flurandrenolide, fluticasone, halcinonide, halobetasol, hydrocortisone, methylprednisolone, mometasone, paramethasone, prednisolone, and triamcinolone. 
     
     
         12 . The method of  claim 10 , wherein the anti-inflammatory compound comprises a non-steroidal anti-inflammatory drug selected from the group consisting of aceclofenac, acemetacin, aminopyrine, azapropazone, benzydamine, bromfenac, bufexamac, carprofen, cinnoxicam, dexketoprofen, diclofenac, diflunisal, dipyrone, etodolac, felbinac, fenbufen, fenoprofen, fentiazac, flufenamic acid, flurbiprofen, ibuprofen, indobufen, indomethacin, indoprofen, ketoprofen, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, niflumic acid, nimesulide, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, a salicylate, sulindac, suprofen, tenoxicam, tiaprofenic acid, tolfenamic acid, and tolmetin. 
     
     
         13 . The method of  claim 10 , wherein the anti-inflammatory compound comprises an immunosuppressant selected from the group consisting of acetretin, alefacept, anakinra, an analgesic, auranofin, azathioprine, cyclophosphamide, cyclosporin, etanercept, isotretinoin, leflunomide, methotrexate, minocycline, montelukast, mycophenalate, penicillamine, pimecrolimus, rosiglitazone, sirolimus, sulfasalazine, tacrolimus, tazarotene, verteporfin, zafirlukast, and zileuton. 
     
     
         14 . The method of  claim 10 , wherein the anti-inflammatory compound comprises an immunotherapeutic selected from the group consisting of an antibody directed against a proinflammatory molecule, adalimumab, efalizumab, infliximab, omalizumab, and mepolizumab. 
     
     
         15 . The method of  claim 10 , wherein the imidazoquinoline amine is a amide substituted imidazoquinoline amine, sulfonamide substituted imidazoquinoline amine, or a urea substituted imidazoquinoline amine. 
     
     
         16 . The method of  claim 10 , wherein the IRM compound is N-[4-(4-amino-2-ethyl-1H-imidazo [4,5-c] quinolin-1-yl)butyl]methanesulfonamide. 
     
     
         17 . The method of  claim 10 , wherein the IRM is N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide and the anti-inflammatory component is prednisone. 
     
     
         18 . The method of  claim 10  wherein the IRM compound and the anti-inflammatory compound are administered at different sites. 
     
     
         19 . The method of  claim 10  wherein the IRM compound and the anti-inflammatory compound are administered at different times. 
     
     
         20 . The method of  claim 10 , wherein the IRM compound is other than 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine. 
     
     
         21 . The method of  claim 10 , wherein the neoplastic tumors are from basal cell carcinoma or actinic keratosis.